Completed PHASE3 NCT00730015

Trial of Linaclotide in Patients With Chronic Constipation

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide Administered Orally for 12 Weeks Followed by a 4-Week Randomized Withdrawal Period in Patients With Chronic Constipation

Sponsor: Forest Laboratories

Conditions Chronic Constipation

Interventions Linaclotide Matching Placebo

Updated 7 times since 2017 Last updated: Dec 19, 2012 Started: Aug 31, 2008 Primary completion: Aug 31, 2009 Completion: Oct 31, 2009

A PHASE3 clinical study on Chronic Constipation, this trial is completed. The trial is conducted by Forest Laboratories and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Forest Laboratories
Ironwood Pharmaceuticals, Inc.

Data source: Ironwood Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Anaheim, United States , Anderson, United States , Annapolis, United States , Asheboro, United States , Asheville, United States , Baltimore, United States , Baton Rouge, United States , Beachwood, United States , Beaumont, United States and 87 more locations